Zila to Report Full Year and Fourth Quarter Fiscal 2006 Results on October 10, 2006
October 06 2006 - 8:30AM
Business Wire
Zila, Inc. (Nasdaq GM: ZILA) will release financial results for the
full year and fourth quarter of its fiscal year ended July 31,
2006, at market close on Tuesday, October 10, 2006. The Company
will also hold a teleconference, which will be simultaneously
webcast, to review the Company's financial results. Any investor or
interested individual can listen to the teleconference, which is
scheduled to begin at 4:30 p.m. EDT (1:30 p.m. PDT) on October 10.
To participate in the teleconference, please call toll-free
877-407-8031 (or 201-689-8031 for international callers)
approximately 10 minutes prior to the above start time. You may
also listen to the teleconference live via the internet at
www.zila.com. A telephone playback of the call will be available
for 48 hours two hours after the completion of the call and can be
accessed by calling 877-660-6853 (or 201-612-7415 for international
callers) and providing passcode 286 and conference ID 215747. The
webcast will be archived on the Company�s website for one week.
About Zila, Inc. Zila, Inc., headquartered in Phoenix, is a leading
cancer diagnostic company initially focused on oral cancer: Zila
Pharmaceuticals is dedicated to establishing ViziLite(R) Plus as
the new standard of care within dental offices nationally for the
early detection of oral abnormalities that could lead to cancer.
Zila Biotechnology is focused on achieving regulatory approval for
the next generation oral cancer diagnostic, OraTest(R), followed by
the development of additional applications of its cancer detection
technologies including products for the early detection of cervical
and esophageal cancer. For more information about Zila, visit
www.zila.com. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2005. Zila, Inc. (Nasdaq GM: ZILA) will
release financial results for the full year and fourth quarter of
its fiscal year ended July 31, 2006, at market close on Tuesday,
October 10, 2006. The Company will also hold a teleconference,
which will be simultaneously webcast, to review the Company's
financial results. Any investor or interested individual can listen
to the teleconference, which is scheduled to begin at 4:30 p.m. EDT
(1:30 p.m. PDT) on October 10. To participate in the
teleconference, please call toll-free 877-407-8031 (or 201-689-8031
for international callers) approximately 10 minutes prior to the
above start time. You may also listen to the teleconference live
via the internet at www.zila.com. A telephone playback of the call
will be available for 48 hours two hours after the completion of
the call and can be accessed by calling 877-660-6853 (or
201-612-7415 for international callers) and providing passcode 286
and conference ID 215747. The webcast will be archived on the
Company's website for one week. About Zila, Inc. Zila, Inc.,
headquartered in Phoenix, is a leading cancer diagnostic company
initially focused on oral cancer: -- Zila Pharmaceuticals is
dedicated to establishing ViziLite(R) Plus as the new standard of
care within dental offices nationally for the early detection of
oral abnormalities that could lead to cancer. -- Zila Biotechnology
is focused on achieving regulatory approval for the next generation
oral cancer diagnostic, OraTest(R), followed by the development of
additional applications of its cancer detection technologies
including products for the early detection of cervical and
esophageal cancer. For more information about Zila, visit
www.zila.com. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2005.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024